3-Year VenoValve First-In-Human Data Presented At 49th Annual VEITH Symposium On Vascular And Endovascular Issues
3-Year VenoValve First-In-Human Data Presented At 49th Annual VEITH Symposium On Vascular And Endovascular Issues
在第49届VEITH血管和血管内问题年度研讨会上公布了为期3年的VenoValve人类首次数据
First-in-Human VenoValve recipients continue to benefit from VenoValve at average of 3 years post-surgery
No venous ulcer recurrences or CVI relapses
Stability in improvements for all study endpoints including reflux, disease severity (rVCSS), and pain (VAS)
首次在人体的VenoValve接受者平均在手术后3年内继续受益于VenoValve
无静脉溃疡复发或 CVI 复发
所有研究终点改善的稳定性,包括反流、疾病严重程度 (rvCS) 和疼痛 (VAS)
IRVINE, CA / ACCESSWIRE / November 17, 2022 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that Principal Investigator Dr. Jorge Hernando Ulloa presented positive long-term, three-year observational data from a cohort of patients that participated in the previously concluded VenoValve first-in-human clinical trial.
加利福尼亚州尔湾/Accesswire/2022 年 11 月 17 日/ 制定静脉疾病治疗新护理标准的公司EnvVeno Medical Corporation(纳斯达克股票代码:NVNO)(“EnvVeno” 或 “公司”)今天宣布,首席研究员豪尔赫·埃尔南多·乌洛亚博士提供了参与先前结束的VenoValve首次人体临床试验的一组患者的三年期积极观察数据。
The data...
在纽...
登录免费看全文
登录/注册